ImmunoCellular Therapeutics, Ltd.   Report issue

For profit Phase 1 Phase 3
Founded: Calabasas CA United States (2006)
Status: Acquired by EOM Pharmaceuticals (2021)

Organization Overview

First Clinical Trial
2011
NCT01280552
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (1)

ict-107 (2 trials)

Drugs in Phase 1 Trials (1)

ict-121 dc vaccine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glioblastoma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2